Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

CytoDyn's leronlimab reaffirms HIV potential with macaque study

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

CytoDyn's leronlimab showed potential for HIV treatment in a macaque study where the triple combination therapy eradicated the virus in infant primates, supporting progression to human trials despite previous regulatory setbacks.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.

◆ ◆ The Wire takeaway

You must prepare for leronlimab's next phase in the HIV treatment race as it gains fresh proof from primate models; this opens a rare path to revisit regulatory approvals and clinical trial design in HIV cure efforts.

◆ Coverage

1 source · 12 Aug 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryhivleronlimabmacque-studyantiretroviraltherapybiotech